Omeprazole Noridem (Omeprazole Sodium)

Omeprazole Noridem is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related gastrointestinal conditions:

• Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining.
• Erosive oesophagitis: accelerates mucosal healing and reduces further erosion.
• Peptic ulcer disease (duodenal and gastric ulcers): supports ulcer healing and helps prevent recurrence.
• Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with the disorder.

• Omeprazole sodium is a pro‑drug that is absorbed in the small intestine and converted to its active sulphenic acid form in the acidic environment of the secretory canaliculi of parietal cells. The active metabolite covalently binds to cysteine residues of the H⁺/K⁺‑ATPase (the gastric proton pump), resulting in irreversible inhibition of acid secretion and prolonged elevation of gastric pH.

Adverse reactions to Omeprazole Noridem are generally mild to moderate and vary in frequency.

Common Side Effects

• Headache: mild, transient headache reported by some patients.
• Diarrhoea: loose stools occurring during early treatment.
• Nausea: occasional feeling of queasiness.
• Abdominal pain: mild discomfort in the stomach region.
• Flatulence: increased intestinal gas.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): difficulty breathing, swelling of face or throat.
• Clostridioides difficile infection: persistent watery diarrhoea, fever.
• Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat.
• Bone fractures: increased risk of hip, wrist or spine fractures with long‑term use.
• Liver enzyme elevation: raised ALT/AST on laboratory testing.
• Interstitial lung disease: rare inflammation of lung tissue presenting with cough and breathlessness.

When prescribing Omeprazole Noridem, clinicians should consider several safety aspects:

• Assess renal function: dose adjustment may be required in severe renal impairment.
• Evaluate hepatic function: use with caution in patients with moderate to severe liver disease.
• Monitor long‑term use: prolonged therapy has been linked to nutrient deficiencies and bone density loss.
• Review concomitant medications: potential for drug‑drug interactions, especially with antiplatelet agents.
• Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Omeprazole Noridem can affect the pharmacokinetics of several co‑administered medicines. Awareness of the interaction potential helps optimise therapy.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, may increase cardiovascular event risk.
• Atazanavir: markedly decreased absorption, loss of antiviral efficacy.
• Dasatinib: lowered plasma concentrations, reduced therapeutic effect.

Moderate Interactions (Monitor Closely)

• Warfarin: possible increase in INR, monitor coagulation parameters.
• Phenytoin: decreased serum levels, watch for seizure control.
• Methotrexate (high dose): increased exposure, monitor for toxicity.